Company Updates
Insync’s Global Equity Funds deliver +30% returns in 2019
Our four key pillars for business success are now in place – Product, Process, People and Performance.
Finally, a transparent energy marketplace is here
More choice. Less cost. Scalable. Energy source neutral and pro-renewables at the same time.
Silicon Valley tech investors join in seed round after Transactor clicks over $2B worth of property transactions
Transactor clicks over $2B worth of property transactions and attracts investment and advisory from major Silicon Valley tech investors such as Adrian Salamunivic Best selling author of Free Pr and be
Amber in 2019: More users, more funding more awards
Australian Bitcoin Startup closes another $400k in funding & wins Finovate Middle East “best of show” award
ThinkMarkets launched groundbreaking new trading platform; announced ‘Think 2020’ initiative to help young people in partnership with cricket legend Glenn McGrath
019 has been a year of significant growth and global expansion for ThinkMarkets, culminating in the launch of ThinkTrader – a groundbreaking new financial trading platform built
Launch of the ResiFund sees it on track to deliver 10%+ return in year one and significantly outperform the market
Launch of the first Residential property fund of its kind, offering a superior way to invest in residential property and access to properties not available to most wholesale investors
Kingdom Developments releases Progress Report
The future looks promising for our developments in Sydney, Wollongong and Queensland. The following report provides an insight into current trends and the investment return that can be expected over t
Total Blood Profile has had a third patent granted for our rapid diagnostic tests in the US
Total Blood Profile has had a third patent granted for our rapid diagnostic tests in the US
Kazia, an Australian oncology-focused biotechnology company is pleased to announce the results of its Extraordinary General Meeting of shareholders
Sydney, 20 December 2019 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the results of its Extraordinary General
Backed By Leading Investment Groups and Family Offices
